137 related articles for article (PubMed ID: 22252805)
1. Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.
Stoddart CA; Nault G; Galkina SA; Bousquet-Gagnon N; Bridon D; Quraishi O
Antimicrob Agents Chemother; 2012 Apr; 56(4):2162-5. PubMed ID: 22252805
[TBL] [Abstract][Full Text] [Related]
2. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.
Stoddart CA; Nault G; Galkina SA; Thibaudeau K; Bakis P; Bousquet-Gagnon N; Robitaille M; Bellomo M; Paradis V; Liscourt P; Lobach A; Rivard ME; Ptak RG; Mankowski MK; Bridon D; Quraishi O
J Biol Chem; 2008 Dec; 283(49):34045-52. PubMed ID: 18809675
[TBL] [Abstract][Full Text] [Related]
3. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.
Cong ME; Youngpairoj AS; Zheng Q; Aung W; Mitchell J; Sweeney E; Hanson DL; Hendry RM; Dobard C; Heneine W; García-Lerma JG
J Virol; 2011 Aug; 85(15):7933-6. PubMed ID: 21632769
[TBL] [Abstract][Full Text] [Related]
4. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
[TBL] [Abstract][Full Text] [Related]
5. Truvada for HIV prophylaxis in heterosexual patients.
DeDea L
JAAPA; 2012 Oct; 25(10):14. PubMed ID: 23115862
[No Abstract] [Full Text] [Related]
6. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
7. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver.
Kollmann TR; Pettoello-Mantovani M; Katopodis NF; Hachamovitch M; Rubinstein A; Kim A; Goldstein H
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3126-31. PubMed ID: 8610180
[TBL] [Abstract][Full Text] [Related]
9. Emtricitabine/tenofovir disoproxil fumarate.
Dando TM; Wagstaff AJ
Drugs; 2004; 64(18):2075-82; discussion 2083-4. PubMed ID: 15341498
[TBL] [Abstract][Full Text] [Related]
10. Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.
Blackwell CW
Nurse Pract; 2014 Sep; 39(9):50-3. PubMed ID: 25140852
[TBL] [Abstract][Full Text] [Related]
11. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
[TBL] [Abstract][Full Text] [Related]
12. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
[TBL] [Abstract][Full Text] [Related]
13. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1.
Kollmann TR; Pettoello-Mantovani M; Zhuang X; Kim A; Hachamovitch M; Smarnworawong P; Rubinstein A; Goldstein H
J Exp Med; 1994 Feb; 179(2):513-22. PubMed ID: 8294863
[TBL] [Abstract][Full Text] [Related]
14. Trial success spurs planning for rollout of HIV prevention pills.
Dolgin E
Nat Med; 2011 Apr; 17(4):392. PubMed ID: 21475207
[No Abstract] [Full Text] [Related]
15. Preexposure prophylaxis for HIV infection.
Steinbrook R
JAMA; 2012 Sep; 308(9):865-6. PubMed ID: 22820712
[No Abstract] [Full Text] [Related]
16. Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms.
Kovalev G; Duus K; Wang L; Lee R; Bonyhadi M; Ho D; McCune JM; Kaneshima H; Su L
J Immunol; 1999 Jun; 162(12):7555-62. PubMed ID: 10358212
[TBL] [Abstract][Full Text] [Related]
17. Ethical challenges of preexposure prophylaxis for HIV.
Jay JS; Gostin LO
JAMA; 2012 Sep; 308(9):867-8. PubMed ID: 22847147
[No Abstract] [Full Text] [Related]
18. Combining 25-Hydroxycholesterol with an HIV Fusion Inhibitor Peptide: Interaction with Biomembrane Model Systems and Human Blood Cells.
Gomes B; Sanna G; Madeddu S; Hollmann A; Santos NC
ACS Infect Dis; 2019 Apr; 5(4):582-591. PubMed ID: 30816690
[TBL] [Abstract][Full Text] [Related]
19. A perspective on progress and gaps in HIV prevention science.
Kiser PF; Mesquita PM; Herold BC
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871
[TBL] [Abstract][Full Text] [Related]
20. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
Stoddart CA; Joshi P; Sloan B; Bare JC; Smith PC; Allaway GP; Wild CT; Martin DE
PLoS One; 2007 Nov; 2(11):e1251. PubMed ID: 18043758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
